Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: Two unique but complementary strategies for the treatment of allergic diseases

Journal of Allergy and Clinical Immunology

Volumn 110, Issue 5, 2002, Pages 706-712

  Horner, Anthony Adam ^a   Raz, Eyal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytosine phosphate guanine motif; Immunomodulation; Immunostimulatory DNA; Immunotherapy

Indexed keywords

ALLERGEN; CYTOKINE; DNA VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; HISTAMINE; IMMUNOSTIMULATING AGENT; IMMUNOSTIMULATORY SEQUENCE OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 10; OLIGODEOXYNUCLEOTIDE; OVALBUMIN; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ALLERGY; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ATOPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPG ISLAND; DNA SEQUENCE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0036858610     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.129122     Document Type: Article

References (54)

1. Holgate ST. The epidemic of allergy and asthma. Nature 1999;402(6760 suppl):B2-4.
2. Graham LM. Balancing safety and efficacy in the treatment of pediatric asthma. J Allergy Clin Immunol 2002;109(suppl):560S-6S.
3. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and anti-histamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:949-55.
4. Creticos PS. Immunotherapy. In: Kaplan AP, editor. Allergy. 2nd Ed. Philadelphia: Saunders; 1997. p. 726-39.
5. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997;99:744-51.
6. Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324-31.
7. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501-6.
8. Horner AA, Van Uden JH, Zubeldia JM, Broide D, Raz E. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol Rev 2001;179:102-18.
9. Creticos PS, Balcer SL, Schroeder JT, et al. Initial immunotherapy trial to explore the safety, tolerability, and immunogenicity of subcutaneous injection of the AMB a 1 immunostimulatory oligonucleotide conjugate (AIC) in ragweed allergic adults. J Allergy Clin Immunol 2001;107(suppl):S216.
10. Creticos PS, Eiden JJ, Balcer SL. et al. Immunostimulatory oligodeoxynucleotides conjugated to Amb a 1: Safety, skin test reactivity, and basophil histamine release [abstract]. J Allergy Clin Immunol 2000;105(suppl):S70.
11. Raz E, Tighe H, Sato Y, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A 1996;93:5141-5.
12. Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-4.
13. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997;158:3635-9.
14. Freund J, Casals J, Hosmer EP. Sensitization and antibody formation after injection of tubercule bacilli and paraffin oil. Proc Soc Exp Biol Med 1937;37:509-13.
15. Tokunaga T, Yamamoto H, Shimada S, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984;72:955-62.
16. Yamamoto S, Kuramoto E, Shimada S, Tokunaga T. In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 1988;79:866-73.
17. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 1992;148:4072-6.
18. Horner AA, Widhopf GF, Burger JA. et al. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J Allergy Clin Immunol 2001;108:417-23.
19. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest 1996;98:1119-29.
20. Bird AP. DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res 1980;8:1499-504.
21. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
22. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996;93:2879-83.
23. Van Uden J, Raz E. Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol 1999;104:902-910.
24. Schwartz DA, Wohlford-Lenane CL, Quinn TJ, Krieg AM. Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol 1999;163:224-31.
25. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7.
26. Martin-Orozco E, Kobayashi H, Van Uden J, Nguyen MD, Kornbluth RS, Raz E. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol 1999;11:1111-8.
27. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849-54.
28. Horner AA, Ronaghy A, Cheng PM, et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol 1998;190:77-82.
29. McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998;161:4463-6.
30. Horner AA, Nguyen MD, Ronaghy A, Cinman N, Verbeek S, Raz E. DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice. J Allergy Clin Immunol 2000;106:349-56.
31. Kohama Y, Akizuki O, Hagihara K, Yamada E, Yamamoto H. Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice. J Allergy Clin Immunol 1999;104:1231-8.
32. Kobayashi H, Horner AA, Takabayashi K, et al. Immunostimulatory DNA pre-priming: A novel approach for prolonged Th1-biased immunity. Cell Immunol 1999;198:69-75.
33. Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 2000;165:1228-35.
34. Kline JN, Waldschmidt TJ, Businga TR, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998;160:2555-9.
35. Horner AA, Datta SK, Takabayashi K, et al. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol 2001;167:1584-91.
36. Horner AA, Takabayashi K, Beck L, et al. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J Allergy Clin Immunol 2002;110:413-20.
37. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98-106.
38. Shirota H, Sano K, Hirasawa N, et al. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 2001;167:66-74.
39. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002;109:455-62.
40. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000;30:1939-47.
41. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124-34.
42. Broide D, Schwarze J, Tighe H, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998;161:7054-62.
43. Magone MT, Chan CC, Beck L, Whitcup SM, Raz E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 2000;30:1841-50.
44. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999;162:6284-93.
45. Serebrisky D, Teper AA, Huang CK, et al. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J Immunol 2000;165:5906-12.
46. Broide DH, Stachnick G, Castaneda D, et al. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J Clin Immunol 2001;21:175-82.
47. Bohle B, Jahn-Schmid B, Maurer D, Kraft D, Ebner C. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN- gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol 1999;29:2344-53.
48. Fujieda S, Iho S, Kimura Y, Yamamoto H, Igawa H, Saito H. Synthetic oligodeoxynucleotides inhibit IgE induction in human lymphocytes. Am J Respir Crit Care Med 2000;162:232-9.
49. Yamamoto T, Yamamoto S, Kataoka T, Komuro K, Kohase M, Tokunaga T. Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res 1994;85:775-9.
50. Parronchi P, Brugnolo F, Annunziato F, et al. Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Th1 effectors. J Immunol 1999;163:5946-53.
51. Broide D, Raz E. DNA-Based immunization for asthma. Int Arch Allergy Immunol 1999;118:453-6.
52. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-94.
53. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic diseases: Revisiting the hygiene hypothesis. Nat Rev Immunol 2001;1:69-75.
54. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001;2:725-31.